Ada Medical, a research partnership group based in Toronto, Canada that provides clinical-trial services to the pharmaceutical, biotechnology and medical device industries, is expanding into the preclinical space through a collaboration with specialist Italian contract research organisation Ephoran Multi-Imaging Solutions.
Under the arrangement, Ephoran will use its molecular-imaging technology to conduct preclinical drug-development modelling and assessments focused on oncology as well as cardiovascular and inflammatory diseases.
Based near Turin in Bioindustry Park Silvano Fumero, the company is a reference centre for a number of imaging technologies, ADA Medical said, adding that Ephoran’s new role “fills a void in the preclinical drug imaging sector, namely new product verification prior to filling an Investigational New Drug Application”.
ADA Medical specialises in trial management and support for hospital-based as well as outpatient clinical studies from Phase IIb to Phase IV. Its trial sites are all located in Canada.
Cost-effective development
“Ephoran’s molecular imaging expertise will bring a much-needed new technology to the market to assist drug and biotech companies in expediting cost-effective development of new compounds to clinical trials,” commented Renzo DiCarlo, chief executive officer of ADA Medical.
Di Carlo is also CEO of ADA Medical’s sister company Biopharma Services, which operates out of the same site in Toronto.
Together, the two businesses can now offer a full range of contract -research services, from early pre-clinical drug development through to Phase I-IV clinical trials, he noted.
